Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson HF Jr.

Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.

2.

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK.

Mod Pathol. 2009 Sep;22(9):1243-50. doi: 10.1038/modpathol.2009.92. Epub 2009 Jun 12.

3.

Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.

Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, Ahn G, Shin YK.

Histol Histopathol. 2007 Nov;22(11):1185-95. doi: 10.14670/HH-22.1185.

PMID:
17647191
4.

PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.

Lohneis P, Darb-Esfahani S, Dietel M, Braicu I, Sehouli J, Arsenic R.

Anticancer Res. 2015 Nov;35(11):6329-34.

PMID:
26504072
5.

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.

Clin Cancer Res. 2004 Oct 1;10(19):6432-6.

6.

The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.

King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK.

Am J Surg Pathol. 2011 Jun;35(6):904-12. doi: 10.1097/PAS.0b013e318212ae22.

7.

Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.

Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, Schrijver I, Longacre TA.

Am J Surg Pathol. 2008 Jul;32(7):1029-37. doi: 10.1097/PAS.0b013e31816380c4.

PMID:
18469706
8.

BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE.

Virchows Arch. 2014 Jun;464(6):701-7. doi: 10.1007/s00428-014-1577-7. Epub 2014 Apr 23.

PMID:
24756216
9.

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.

Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA.

Gynecol Oncol. 2005 Mar;96(3):684-94.

PMID:
15721412
10.

Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.

Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B.

Gynecol Oncol. 2015 Oct;139(1):30-9. doi: 10.1016/j.ygyno.2015.07.107. Epub 2015 Jul 29.

PMID:
26232338
11.

B7-H4 overexpression in ovarian tumors.

Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.

Gynecol Oncol. 2006 Jan;100(1):44-52. Epub 2005 Oct 26.

PMID:
16256178
12.

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.

Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.

Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.

13.

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.

Gynecol Oncol. 2006 Nov;103(2):405-16. Epub 2006 May 24.

PMID:
16725184
14.

Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.

Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM.

Int J Cancer. 2006 Aug 1;119(3):599-607.

15.

Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.

Shih IeM, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL.

Mod Pathol. 2011 May;24(5):638-45. doi: 10.1038/modpathol.2010.230. Epub 2011 Jan 14.

16.

Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma.

Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL, Shih IeM.

Hum Pathol. 2006 Sep;37(9):1169-75. Epub 2006 Jul 7.

PMID:
16938522
17.

Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.

Lee M, Nam EJ, Kim SW, Kim S, Kim JH, Kim YT.

Int J Gynecol Cancer. 2012 Nov;22(9):1489-96. doi: 10.1097/IGJ.0b013e3182738307.

PMID:
23095773
18.

Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.

Canet B, Pons C, Espinosa I, Prat J.

Hum Pathol. 2011 Jun;42(6):833-9. doi: 10.1016/j.humpath.2010.08.022. Epub 2011 Jan 3.

PMID:
21208644
19.

Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML.

Cancer Res. 2010 Mar 1;70(5):1906-15. doi: 10.1158/0008-5472.CAN-09-3875. Epub 2010 Feb 23.

20.

Loss of p16INK4A expression in low-grade ovarian serous carcinomas.

Schlosshauer PW, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S, Pearl M, Yang Z, Sheng T, Dong J.

Int J Gynecol Pathol. 2011 Jan;30(1):22-9. doi: 10.1097/PGP.0b013e3181ed89b3. Erratum in: Int J Gynecol Pathol. 2011 May;30(3):314.

PMID:
21131838

Supplemental Content

Support Center